Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1793 1
1801 1
1827 1
1844 1
1848 2
1849 1
1851 4
1852 5
1855 1
1858 2
1859 1
1861 1
1863 1
1865 1
1867 1
1868 1
1869 1
1872 1
1875 1
1877 2
1879 1
1880 1
1881 1
1883 2
1886 1
1887 1
1889 3
1890 2
1891 2
1892 2
1893 3
1894 2
1895 1
1896 1
1898 1
1899 3
1900 1
1901 2
1902 3
1903 3
1907 2
1908 1
1909 3
1911 1
1912 1
1914 1
1916 7
1917 2
1918 1
1919 3
1920 3
1921 2
1922 3
1923 9
1924 2
1925 1
1926 1
1927 2
1928 1
1929 2
1930 2
1931 3
1932 2
1933 2
1934 1
1935 2
1937 4
1938 1
1939 1
1941 4
1942 2
1943 2
1944 3
1945 4
1946 21
1947 37
1948 19
1949 16
1950 37
1951 28
1952 30
1953 27
1954 24
1955 22
1956 27
1957 30
1958 40
1959 34
1960 25
1961 14
1962 37
1963 40
1964 46
1965 46
1966 67
1967 46
1968 52
1969 46
1970 39
1971 41
1972 47
1973 37
1974 39
1975 58
1976 68
1977 57
1978 59
1979 62
1980 81
1981 57
1982 65
1983 77
1984 68
1985 73
1986 82
1987 97
1988 99
1989 104
1990 87
1991 93
1992 119
1993 106
1994 90
1995 111
1996 122
1997 123
1998 129
1999 116
2000 120
2001 124
2002 140
2003 114
2004 146
2005 166
2006 159
2007 187
2008 160
2009 148
2010 160
2011 174
2012 210
2013 184
2014 193
2015 170
2016 171
2017 173
2018 196
2019 206
2020 222
2021 192
2022 183
2023 187
2024 172
2025 208
2026 97

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,490 results

Results by year

Filters applied: . Clear all
Page 1
[No title available]
Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, Banerji A, Bara NA, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Busse PJ, Bygum A, Caballero T, Cancian M, Castaldo A, Cohn DM, Csuka D, Farkas H, Gompels M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Kang HR, Kaplan AP, Katelaris C, Kiani-Alikhan S, Lei WT, Lockey R, Longhurst H, Lumry WR, MacGinnitie A, Malbran A, Saguer IM, Matta JJ, Nast A, Nguyen D, Nieto-Martinez SA, Pawankar R, Peter J, Porebski G, Prior N, Reshef A, Riedl M, Ritchie B, Sheikh FR, Smith WB, Spaeth PJ, Stobiecki M, Toubi E, Varga LA, Weller K, Zanichelli A, Zhi Y, Zuraw B, Craig T. Maurer M, et al. Among authors: smith wb. Arerugi. 2023;72(8):1084. doi: 10.15036/arerugi.72.1084. Arerugi. 2023. PMID: 37730355 Japanese. No abstract available.
Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).
Smith WE, Berry SA, Bloom K, Brown C, Burton BK, Demarest OM, Jenkins GP, Malinowski J, McBride KL, Mroczkowski HJ, Scharfe C, Vockley J; ACMG Board of Directors. Electronic address: documents@acmg.net. Smith WE, et al. Genet Med. 2025 Jan;27(1):101289. doi: 10.1016/j.gim.2024.101289. Epub 2024 Dec 4. Genet Med. 2025. PMID: 39630157 Free article.
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Abboud MR, Cançado RD, De Montalembert M, Smith WR, Rimawi H, Voskaridou E, Güvenç B, Ataga KI, Keefe D, Grosch K, Watson J, Reshetnyak E, Nassin ML, Dei-Adomakoh Y. Abboud MR, et al. Among authors: smith wr. Lancet Haematol. 2025 Apr;12(4):e248-e257. doi: 10.1016/S2352-3026(24)00384-3. Epub 2025 Mar 12. Lancet Haematol. 2025. PMID: 40088922 Clinical Trial.
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR. Idowu M, et al. Among authors: smith wr. Lancet Haematol. 2025 Jan;12(1):e35-e44. doi: 10.1016/S2352-3026(24)00319-3. Epub 2024 Dec 4. Lancet Haematol. 2025. PMID: 39644907 Clinical Trial.
Making Decisions.
Smith WM 2nd. Smith WM 2nd. J Grad Med Educ. 2023 Aug;15(4):509-510. doi: 10.4300/JGME-D-23-00012.1. J Grad Med Educ. 2023. PMID: 37637330 Free PMC article. No abstract available.
Reply.
Ali SB, Smith W. Ali SB, et al. Among authors: smith w. J Allergy Clin Immunol Glob. 2025 Mar 20;4(2):100460. doi: 10.1016/j.jacig.2025.100460. eCollection 2025 May. J Allergy Clin Immunol Glob. 2025. PMID: 40242147 Free PMC article. No abstract available.
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel.
Fuente J, Frangoul H, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara MY, Liem RI, Rupprecht J, Kuo KHM, Merkeley H, Algeri M, Smith W, Kohli P, Li N, Rubin J, Zhang S, Hobbs W, Locatelli F. Fuente J, et al. Among authors: smith w. Blood Adv. 2025 Dec 23;9(24):6502-6510. doi: 10.1182/bloodadvances.2025016702. Blood Adv. 2025. PMID: 40862696 Free PMC article. Clinical Trial.
7,490 results